22 hours ago · INDIANAPOLIS, Feb. 6, 2025 /PRNewswire/ -- Eli Lilly and Company (NYSE: LLY) today announced its financial results for the fourth quarter of 2024 and detailed 2025 financial guidance. "2024 was a highly successful year for Lilly," said David A. Ricks, Lilly's chair and CEO."We had major data readouts for tirzepatide in treating chronic disease associated with obesity, invested billions more in ...

22 hours ago · INDIANAPOLIS, Feb. 6, 2025 /PRNewswire/ -- Eli Lilly and Company (NYSE: LLY) today announced its financial results for the fourth quarter of 2024 and detailed 2025 financial guidance. "2024 was a ...

22 hours ago · Eli Lilly and Company (NYSE: LLY) today announced its financial results for the fourth quarter of 2024 and detailed 2025 financial guidance. ... Revenue in Q4 2024 increased 45% to $13.53 billion ...

21 hours ago · Global pharmaceutical company Eli Lilly (NYSE:LLY) met Wall Street’s revenue expectations in Q4 CY2024, with sales up 44.7% year on year to $13.53 billion. ... Eli Lilly (LLY) Q4 CY2024 ...

13 hours ago · Eli Lilly (NYSE: LLY) Q4 2024 Earnings Call Feb 06, 2025, 10:00 a.m. ET. Contents: ... Ladies and gentlemen, thank you for standing by and welcome to the Lilly Q4 2024 earnings call. [Operator ...

22 hours ago · INDIANAPOLIS, Feb. 6, 2025 /PRNewswire/ -- Eli Lilly and Company (NYSE: LLY) today announced its financial results for the fourth quarter of 2024 and detailed 2025 financial guidance. "2024 was a highly successful year for Lilly," said David A. Ricks , …

The Investor Relations website contains information about Eli Lilly and Company's business for stockholders, potential investors, and financial analysts.

22 hours ago · Eli Lilly (LLY) reported strong Q4 2024 financial results with revenue increasing 45% to $13.53 billion, primarily driven by Mounjaro and Zepbound sales.Q4 EPS grew 102% to $4.88 on a reported basis and 114% to $5.32 on a non-GAAP basis. The company received FDA approval for Zepbound for moderate-to-severe obstructive sleep apnea in adults with obesity and Omvoh for Crohn's disease.

19 hours ago · Eli Lilly’s profit doubled in the fourth quarter, propelled by its hot-selling diabetes and obesity treatments, and the drugmaker came out with a mostly better-than-expected 2025 forecast.. Sales of Lilly’s top-selling product, the diabetes treatment Mounjaro, jumped 60% to $3.53 billion in the final quarter of 2024 while its obesity treatment counterpart Zepbound brought in …

14 hours ago · As shown in the Eli Lilly 11, we combine U.S. Incretin Analogs Market through 45% compared to Q4 2023. We increased 3 percentage points in share of market in Q4 2024.